bluebird bio (BLUE) to Release Quarterly Earnings on Monday

bluebird bio (NASDAQ:BLUE) is projected to announce its earnings results on Monday, March 24th. Analysts expect the company to announce earnings of ($6.30) per share and revenue of $27.07 million for the quarter.

bluebird bio Trading Up 0.5 %

NASDAQ BLUE opened at $3.75 on Monday. The company has a market cap of $36.46 million, a price-to-earnings ratio of -0.10 and a beta of 0.76. bluebird bio has a twelve month low of $3.56 and a twelve month high of $30.90. The business’s fifty day moving average is $6.46 and its 200 day moving average is $8.24. The company has a quick ratio of 0.33, a current ratio of 0.51 and a debt-to-equity ratio of 0.37.

Analyst Ratings Changes

Several research analysts have commented on BLUE shares. Barclays lifted their target price on bluebird bio from $2.00 to $40.00 and gave the stock an “overweight” rating in a report on Tuesday, December 31st. JPMorgan Chase & Co. raised bluebird bio from an “underweight” rating to a “neutral” rating in a report on Monday, February 24th. Wells Fargo & Company cut their target price on bluebird bio from $40.00 to $5.00 and set an “equal weight” rating on the stock in a report on Monday, February 24th. Baird R W downgraded bluebird bio from a “strong-buy” rating to a “hold” rating in a report on Friday, February 21st. Finally, StockNews.com assumed coverage on bluebird bio in a research note on Wednesday, March 12th. They issued a “sell” rating on the stock. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $48.10.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.